Relationship of cancer and dual antiplatelet duration to long-term risk of ischaemic and bleeding outcomes after percutaneous coronary intervention.

ABSTRACT:

Aims

The long-term cardiovascular (CV) risks after percutaneous coronary intervention (PCI) in cancer patients are unclear. We assessed the risks of adverse events after PCI related to active or inactive cancer and the duration of dual antiplatelet therapy (DAPT).

Methods and results

This is a retrospective cohort of all patients having PCI with second-generation drug-eluting stents in the national Veterans Affairs Healthcare System between 2008 and 2016. We compared patients with active cancer (cancer and chemotherapy/radiotherapy), inactive cancer (cancer without chemotherapy/radiotherapy), or no cancer using Cox proportional hazards regression models adjusted by the propensity for cancer. Models estimated hazard ratios (HR) and 95% confidence intervals (95% CI) for myocar

SUBMITTER: Ohiomoba R 

PROVIDER: S-EPMC12813285 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature